Highlights:
- Bausch Health Companies' full-year revenue was US$ 8.4 billion for 2021, representing an increase of five per cent year-over-year (YoY).
- During the trading session on Wednesday, February 23, the BHC stock declined 3.3 per cent and closed at C$ 29.16 per share.
- In 2022, Bausch Health Companies expects to clock revenues in the range of US$ 8.4 to US$ 8.6 billion.
Bausch Health Companies Inc. (TSX:BHC) announced fourth quarter fiscal 2021 and provided guidance for this year. In Q4 2021, total reported revenues of Bausch Health Companies were US$ 2,196 billion compared to US$ 2,213 billion in the fourth quarter of 2020.
During the trading session on Wednesday, February 23, the BHC stock declined 3.3 per cent and closed at C$ 29.16 per share.
Also Read: Porsche IPO: Can Canadian investors buy the automaker's stock?
Bausch Health Companies' full-year revenue was US$ 8.4 billion for 2021, representing an increase of five per cent year-over-year (YoY). The overall increase in revenue for the year was due to a 10 per cent YoY growth in revenues of Bausch + Lomb segment.
Financial performance of Bausch Health Companies (TSX:BHC)
According to some analysts, the revenues of Bausch Health Companies for Q4 2021 fell short of expectations. Meanwhile, net income for Q4 2021 was US$ 69 million against a net loss of US$ 153 million in the same comparable quarter of 2020.
In 2021, Bausch Health repaid its debt worth US$ 1.3 billion and used the cash from operations and divestiture of Amoun Pharmaceutical Company S.A.E.
©2022 Kalkine Media®
The operating income of Bausch Health Companies was US$ 367 million in Q4 2021 compared to an operating loss of US$ 5 million in Q4 2020.
In 2021, the company generated a cash of US$ 1.43 billion, an increase of US$ 315 million from 2020. Meanwhile, the adjusted EBITDA rose to US$ 3.5 billion last year, up from US$ 3.3 billion in 2020.
Bottom line
In 2022, Bausch Health Companies expects to clock revenues in the range of US$ 8.4 to US$ 8.6 billion and full-year adjusted EBITDA between US$ 3.45-US$ 3.6 billion.
Apart from providing the full-year guidance, the company revealed some other significant development, which included receiving approval from the Food and Drug Administration for a New Drug Application (NDA) for XIPERE.
Bausch Health Companies has partnered with Lochan LLC to develop eyeTELLIGENCE®, the next-generation clinical decision support software.
In Jordan and South Korea, the company received regulatory approval for LUMIFY, an eye drop for reducing the redness in the eyes.
Also Read: Why is Ocugen (OCGN) stock soaring? Here's what you must know
Please note, the above content constitutes a very preliminary observation or view based on market trends and is of limited scope without any in-depth fundamental valuation or technical analysis. Any interest in stocks or sectors should be thoroughly evaluated taking into consideration the associated risks.